Rhumbline Advisers Otonomy, Inc. Transaction History

Rhumbline Advisers

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 06, 2018	SELL	$3.7 - $4.75 $99,478 - $127,708	-26,886 Closed	0 $0
Q1 2018 May 02, 2018	SELL	$4.05 - $6.1 $7,188 - $10,827	-1,775 Reduced 6.19%	26,886 $113,000
Q4 2017 Feb 09, 2018	SELL	$2.8 - $5.55 $14,753 - $29,242	-5,269 Reduced 15.53%	28,661 $159,000
Q3 2017 Nov 06, 2017	BUY	$3.2 - $20.8 $108,576 - $705,744	33,930	33,930 $110,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.